Zhang M X, Shi W Z, Liu J X, Wang C J, Li Y, Wang W, Jiang B
Department of Hematology, Peking University International Hospital, Beijing 102206, China.
Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, Shanxi, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2021 Oct 18;53(5):915-920. doi: 10.19723/j.issn.1671-167X.2021.05.017.
To investigate the clinical features and prognosis of acute myeloid leukemia (AML) patients with the mixed lineage leukemia () gene rearrangements () positive.
In the study, 11 patients who were newly diagnosed with positive AML were analyzed retrospectively, related literature was reviewed to clarify the clinical features and prognosis of positive patients.
Among the 11 patients, there were 6 males and 5 females, with a median age of 36 years. Six patients were diagnosed with AML M5 and five with M4 according to FAB classification (French-American-British classification systems). Gingival swelling and pain occurred in 6 cases and fever occurred in 5 cases. At first diagnosis, the median white blood cells were 55.5×10/L. Immunotype showed the expression of myeloid/monocyte and early stem cell series antigens. The expression level of fusion gene (real-time quantitative PCR) was 14.2%-214.5%, and 6/11 cases (54.5%) were associated with high gene expression. Mutations of , , , , , and were detected by next generation sequencing (NGS) in 4 patients. Chromosome G banding examination showed that 2 cases were t(6;11)(q27, q23) with complex karyotype abnormality, 4 cases with +8 abnormality and 2 cases with normal karyotype. Hematological complete remission (CR) was achieved in 8/11 patients (72.7%) after conventional induction chemotherapy, and primary drug resistance was observed in 3 patients. Two of the eight patients with CR were negative for minimal residual disease (MRD), with a median CR duration of 4.5 months. Two patients with positive MRD and three patients with refractory recurrence underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), but all died due to leukemia progression. At the end of follow-up on December 1, 2019, 2 patients were alive and 9 died, with median survival time of 9 months.
The AML patients with positive were mostly young, the majority of FAB types were M4 and M5, and most of the patients often had fever as the first symptom, with increased white blood cells, accompanied by organ infiltration, and high gene expression. The hematological remission rate of routine chemotherapy is not low, but it is difficult to achieve molecular remission, most of which have early recurrence. Early allo-HSCT in a molecular negative state may prolong the CR duration.
探讨混合谱系白血病(MLL)基因重排阳性的急性髓系白血病(AML)患者的临床特征及预后。
本研究回顾性分析11例新诊断为MLL阳性AML的患者,并复习相关文献以明确MLL阳性患者的临床特征及预后。
11例患者中,男性6例,女性5例,中位年龄36岁。根据FAB分类(法美英分类系统),6例诊断为AML M5,5例诊断为M4。6例出现牙龈肿胀疼痛,5例出现发热。初诊时,中位白细胞数为55.5×10⁹/L。免疫表型显示髓系/单核细胞及早期干细胞系列抗原表达。MLL融合基因(实时定量PCR)表达水平为14.2% - 214.5%,11例中有6例(54.5%)与MLL基因高表达相关。4例患者通过二代测序(NGS)检测到NRAS、KRAS、FLT3、NPM1、CEBPA及WT1突变。染色体G显带检查显示,2例为t(6;11)(q27,q23)伴复杂核型异常,4例有+8异常,2例核型正常。11例患者中8例(72.7%)经传统诱导化疗后达到血液学完全缓解(CR),3例观察到原发性耐药。8例CR患者中有2例微小残留病(MRD)阴性,CR持续时间中位为4.5个月。2例MRD阳性患者及3例难治复发患者接受了异基因造血干细胞移植(allo-HSCT),但均因白血病进展死亡。至2019年12月1日随访结束时,2例存活,9例死亡,中位生存时间为9个月。
MLL阳性的AML患者多为年轻人,FAB类型以M4和M5为主,多数患者常以发热为首发症状,白细胞增多,伴有器官浸润,且MLL基因表达高。常规化疗血液学缓解率不低,但难以达到分子学缓解,多数早期复发。分子学阴性状态下早期进行allo-HSCT可能延长CR持续时间。